Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to… Read More
Pharmaceutical & biomedical research likely to use $1 billion worth of microfluidics devices by 2016 By Frédéric Breussin The proliferation of lower cost genomics tools, and the maturing of microfluidics lab equipment into more robust tools that better interface with established research flows, could drive microfluidics devices for… Read More
Editing the Human Genome: Role in Functional Genomics and Translational Medicine By Dr Chris Torrance and Eric Rhodes It is now readily accepted that we are in a post genomic era. With the steady flow of genomic information available to researchers worldwide, the focus turns to ways… Read More
New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high… Read More
Ubiquitination, E3 Ligases and Drug Discovery – Novel technologies for a challenging pathway By Dr Neil Wilkie and Dr Steve Davies Does ubiquitin drug discovery provide the opportunity for a new class of therapeutic agents? This article argues that new technological advances are removing many of the… Read More
Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in… Read More
In Vivo Imaging In Drug Development: Gamma Scintigraphy By Dr Alyson Connor Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt,… Read More
By Dr Jeffrey Dage and Dr Kalpana Merchant While the jury is still out in terms of iPS cell technology and its ability to deliver a regenerative therapy or, indeed, contribute to the development of a clinical molecule, this paper argues that the progress by… Read More
The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close… Read More
Pathway Analysis – Understanding the bridge between environmental cues and cellular response By Dr John Comley Understanding the function of a protein in the context of normal and abnormal cellular processes requires a comprehensive knowledge not only of its regulation but also of its role in signalling and… Read More
Biological Analysis and Interpretation For Improved Research Outcomes By Dr Douglas Bassett In the last few years, technological advancements in the life sciences have changed many ways in which we think about research. Next-generation sequencing, qPCR and microRNA offer new avenues to ask and answer research questions in… Read More
Current and Emerging Trends In Immunogenicity Research In November 2011 Drug Discovery World hosted a collegial style roundtable discussion on the present and emerging developments in this fundamental area of drug discovery and development. The participants are drawn from the biopharmaceutical, biotechnology and vendor community. Although somewhat… Read More
Optimising Well Results In Label-Free Analysis By Dr Stephan Heyse, Dr Oliver Leven and Dr Jon Tupy Bearing in mind the cost and time required to conduct a screening campaign, it is of paramount importance that screening laboratory scientists process and analyse screen data as carefully and consistently… Read More
From Outsourced To Open: The continuing evolution of the drug discovery business model Dr Mary Canady One doesn’t have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R&D productivity. However,… Read More
Ontario as a Life Sciences Powerhouse By Michael Stewart Around the world, competition between life sciences companies is fierce. And so is the competition between jurisdictions wanting to attract the good paying jobs, innovative spirit and R&D that comes along with this important economic sector. Read More